Acura Piotroski F Score

ACUR
 Stock
  

USD 0.05  0.00  0.00%   

This module uses fundamental data of Acura Pharma to approximate its Piotroski F score. Acura Pharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Acura Pharma Cmn. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Acura Pharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please continue to Acura Pharma Altman Z Score, Acura Pharma Correlation, Acura Pharma Valuation, as well as analyze Acura Pharma Alpha and Beta and Acura Pharma Hype Analysis.
  
As of 11/28/2022, Total Debt is likely to grow to about 5.7 M. Also, Debt Current is likely to grow to about 7.6 M. Acura Pharma Total Assets Per Share are relatively stable at the moment as compared to the past year. Acura Pharma reported last year Total Assets Per Share of 0.80. As of 11/28/2022, Quick Ratio is likely to grow to 4.89, while Return on Investment is likely to drop (73.34) .
At this time, it appears that Acura Pharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthDecreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesDecreaseFocus
9
Change in Gross MarginNo ChangeFocus

Acura Pharma Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Acura Pharma is to make sure Acura is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Acura Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Acura Pharma's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted9.9 M10.7 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares9.9 M10.7 M
Significantly Down
Increasing
Slightly volatile
Return on Average Assets(72.84)(67.51)
Significantly Down
Decreasing
Slightly volatile
Net Cash Flow from Operations(6.9 M)(6.4 M)
Significantly Down
Decreasing
Stable
Current Liabilities2.5 M3.1 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities5.8 M6.3 M
Significantly Down
Increasing
Slightly volatile
Gross Margin69.8880.91
Fairly Down
Increasing
Slightly volatile
Total Debt5.7 M5.6 M
Slightly Up
Decreasing
Slightly volatile
Asset Turnover0.280.32
Fairly Down
Increasing
Stable
Current AssetsM6.8 M
Fairly Up
Decreasing
Slightly volatile
Total Assets9.7 M9.4 M
Fairly Up
Decreasing
Slightly volatile

Acura Pharma Cmn F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Acura Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Acura Pharma in a much-optimized way.

About Acura Pharma Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

(0.16)

Acura Pharma Book Value per Share is relatively stable at the moment as compared to the past year. Acura Pharma reported last year Book Value per Share of -0.16

Acura Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Acura Pharma from analyzing Acura Pharma's financial statements. These drivers represent accounts that assess Acura Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acura Pharma's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets6.74 M2.57 M2.35 M2.12 M1.91 M1.96 M
Earnings Before Interest Taxes and Depreciation Amortization USD(4.93 M)(3.34 M)(3.05 M)(633 K)(727.95 K)(785.42 K)
Earnings before Tax(5.82 M)(3.84 M)(3.77 M)(1.21 M)(1.39 M)(1.5 M)
Average Equity741.5 K(2.83 M)(4.79 M)(5.46 M)(4.91 M)(5.04 M)
Enterprise Value7.15 M5.53 M9.45 M10.32 M9.29 M9.53 M
Free Cash Flow(4.2 M)(3.91 M)(618 K)(719 K)(826.85 K)(892.13 K)
Invested Capital(777 K)3.83 M5.82 M(3 K)(2.7 K)(2.77 K)
Invested Capital Average636.75 K818.75 K4.17 M1.6 M1.44 M1.48 M
Market Capitalization8.32 M2.42 M4.9 M4.55 M4.09 M4.2 M
Tangible Asset Value3.38 M1.14 M1.75 M1.66 M1.5 M1.54 M
Working Capital(2.06 M)(974 K)104 K(6.34 M)(5.71 M)(5.86 M)

About Acura Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acura Pharma Cmn's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acura Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acura Pharma Cmn based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acura Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now

   

Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Pair Trading with Acura Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acura Pharma

+0.72WFCWells Fargo Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Acura Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharma Cmn to buy it.
The correlation of Acura Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharma Cmn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Acura Pharma Altman Z Score, Acura Pharma Correlation, Acura Pharma Valuation, as well as analyze Acura Pharma Alpha and Beta and Acura Pharma Hype Analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Acura Pharma Cmn price analysis, check to measure Acura Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharma is operating at the current time. Most of Acura Pharma's value examination focuses on studying past and present price action to predict the probability of Acura Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acura Pharma's price. Additionally, you may evaluate how the addition of Acura Pharma to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Please note, there is a significant difference between Acura Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acura Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acura Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.